treatment | Page 54 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

  1. Home

Living in an online world: Social media experiences of adolescents and young adults with cancer

Abstract
Background
Despite widespread use, little is known about how adolescents and young adults (AYA) with cancer use social media (SM). This research characterized use and self-reported SM experiences among AYA with cancer.

Procedure
AYA, aged 12-26 years, receiving cancer care completed a mixed-methods survey regarding SM experiences. Clinical information was obtained from the electronic medical record. Data were analyzed with descriptive statistics, t tests, and qualitative content analysis.

Sabatolimab

Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukemic cells. Sabatolimab also binds to TIM-3 on leukemic cells, potentially impeding self-renewal of LSCs via inhibition of TIM3-galectin-9.

Zohra Nooruddin, MD

Nooruddin, Zohra
Mays Cancer Center at UT Health San Antonio MD Anderson

Zohra Nooruddin, MD received her medical degree from Ziauddin Medical University in Karachi, Pakistan, and attended Mount Sinai School of Medicine in Englewood, New Jersey for her residency. Dr. Nooruddin completed a fellowship in symptom control and palliative care at The University of Texas MD Anderson Cancer Center in Houston, and a fellowship in hematology-oncology at the University of Colorado Denver. She is board-certified in hospice and palliative medicine, and in hematology and oncology.

Online Profile: 

Anand Karnad, MD

Karnad, Anand
Mays Cancer Center at UT Health San Antonio MD Anderson

Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center.

Online Profile: 
https://cancer.uthscsa.edu/doctors-and-locations/doctors-and-clinics/anand-karna…